



Navigate-AD

An Alzheimer's Research Study

Aim

To evaluate the safety and tolerability of 3mg and 12mg of the β secretase inhibitor (LY3202626) in participants with mild Alzheimer's disease over a 12-month treatment period.

Phase II

Effect of LY3202626 on Alzheimer's disease progression as measured by cerebral 18F-AV-1451 Tau-PET in mild Alzheimer's disease dementia, in comparison to placebo.

Hypothesis

β secretase inhibition lowers $A\beta$ peptide and thereby limits neurodegeneration by reducing tau propagation, as measured by Tau-PET.

TGA Trial: NCT02791191

Status

Enrolment to commence November 2016

Funding

- Eli Lilly Australia Pty Limited
- Neurodegenerative Disorders Research Pty Ltd

Criteria

To be eligible for the Navigate-AD Study participants must:

- be 55-85 years of age,
- have mild Alzheimer's dementia (NIA-AA),
- have a MMSE score between 20 to 26
- Florbetapir PET scan consistent with presence of Amyloid.

Ethics approval

Austin Health Human Research Ethics Committee (HREC/16/Austin/118)

Contact

Professor Peter K Panegyres, MD PhD FRACP
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005

Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au